Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) and Immunocore (NASDAQ:IMCR – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.
Earnings & Valuation
This table compares Valion Bio, Inc. Common Stock and Immunocore”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Valion Bio, Inc. Common Stock | $780,000.00 | 1.07 | -$8.88 million | ($159.25) | -0.01 |
| Immunocore | $400.02 million | 3.99 | -$35.51 million | ($0.37) | -83.73 |
Valion Bio, Inc. Common Stock has higher earnings, but lower revenue than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Valion Bio, Inc. Common Stock and Immunocore’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Valion Bio, Inc. Common Stock | N/A | -193.17% | -67.10% |
| Immunocore | -4.20% | -4.54% | -1.66% |
Risk & Volatility
Valion Bio, Inc. Common Stock has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Valion Bio, Inc. Common Stock and Immunocore, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Valion Bio, Inc. Common Stock | 1 | 0 | 0 | 0 | 1.00 |
| Immunocore | 1 | 4 | 6 | 1 | 2.58 |
Immunocore has a consensus target price of $56.38, indicating a potential upside of 81.97%. Given Immunocore’s stronger consensus rating and higher possible upside, analysts plainly believe Immunocore is more favorable than Valion Bio, Inc. Common Stock.
Institutional & Insider Ownership
4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 0.9% of Valion Bio, Inc. Common Stock shares are owned by insiders. Comparatively, 10.1% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Immunocore beats Valion Bio, Inc. Common Stock on 11 of the 15 factors compared between the two stocks.
About Valion Bio, Inc. Common Stock
Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
About Immunocore
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company’s product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Receive News & Ratings for Valion Bio Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valion Bio Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
